Rituximab Plus CEAC: No Survival Advantage in DLBCL
In the evolving landscape of oncology, particularly targeting hematological malignancies, innovative therapeutic strategies consistently attract significant attention. A recent pivotal ...
Tag: monoclonal antibodies in oncology
Ring-Opening Linker Boosts HER2-Targeting ADCs Safety
In a groundbreaking advancement poised to reshape the landscape of targeted cancer therapies, researchers have unveiled a novel conjugation strategy ...
Comparing Immune Responses: Rituximab vs. Obinutuzumab in Follicular Lymphoma
Recent advancements in oncology have brought to light significant findings regarding the immunologic responses prompted by various therapeutic regimens for ...
Soaring Challenges in Antibody-Drug Conjugates: Navigating Target Selection and Managing Side Effects
Antibody-Drug Conjugates (ADCs) represent a dynamic and rapidly evolving frontier in targeted cancer therapy, combining the specificity of monoclonal antibodies ...
New Insights: Outside-In Signaling Pathway Linked to Cancer Cell Entry
A groundbreaking new study has emerged that details the intricate mechanism through which an anticancer drug is ushered into cancer ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!